A 59-year-old woman with refractory uveitis.

Authors

Lisa R Koenig, Eli L Diamond, Jasmine H Francis

Published in

Retinal cases & brief reports. Jul 21, 2026. Epub Jul 21, 2026.

Abstract

To describe a novel use of melphalan delivered via ophthalmic artery chemosurgery (OAC) in the treatment of refractory histiocytosis, and to demonstrate a durable response at four years of follow-up.
Case report.
We present a case of histiocytosis, specifically Rosai-Dorfman-Destombes disease (RDD), masquerading as refractory anterior uveitis and nodular scleritis. The patient was effectively treated with cobimetinib and melphalan via OAC. The ophthalmic manifestations remain resolved, and the visual acuity is 20/20 at four years of follow-up.
The novel and durable use of OAC melphalan in the management of ophthalmic RDD is described herein.

PMID:
42479547
Bibliographic data and abstract were imported from PubMed on 22 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.